RTP-based TransEnterix stock up on news of SurgiBot sale

Research Triangle Park-based TransEnertix (NYSEMKT:TRXC) stock is up nearly 9 percent to $2.31 a share in pre-market trading Tuesday following news that it has agreed to sell its SurgiBot system to a Chinese firm for $29 million. The FDA rejected TransEnterix’s Surgibot submission last year. The medical device company agreed to transfer ownership of the SurgiBot line to China’s Great Belief International Limited (GBIL). TranEnterix will receive $7.5 million by the end of December and another $7.5 million by March, 2018. The second payment includes a $3 million equity investment in Transeneterix common stock at $2.33 a share. The...

Read More